Health Care Qui Tam Update

by Mintz
Contact

Mintz

[co-author: Amanda Clairmont, Law Clerk]

In this issue, we provide an overview of 62 recently unsealed qui tam cases and take an in-depth look at four of those cases. Two of the featured cases concern alleged schemes to provide unnecessary therapy to residents of skilled nursing facilities, while another illustrates the government’s increasing use of claim information from the Medicare database to investigate potential false claims. In addition, we discuss health care qui tam litigation trends based on filings in the 12-month period that ended on August 31, 2018, including the continued diversification of case filers. Although current and former employees still file the majority of qui tam cases, a growing number of relators are former business partners or consultants, industry experts, and patients.

Overview of Qui Tam Activity

  • We identified 62 health care-related qui tam cases that were unsealed in June and July 2018.
  • The government intervened in whole or in part in 16% of those 62 unsealed cases. This is consistent with the overall intervention rate during the prior 12 months.
  • Twenty-five of the 62 unsealed cases were dismissed in their entirety and two settled. Thirty-four cases — or 55% of the cases we identified — were ongoing as of the time of our search. The status of one case could not be determined from the unsealed documents.
  • The 62 unsealed cases were filed in 37 different courts. The active Middle District of Florida (Jacksonville, Orlando, and Tampa) once again led all jurisdictions, with five unsealed cases. Four cases were unsealed in the Eastern District of Pennsylvania (Philadelphia), the Middle District of Tennessee (Nashville), and the Southern District of Florida (Miami, Fort Lauderdale, and West Palm Beach). The Eastern District of California (Fresno, Sacramento), Northern District of Georgia (primarily Atlanta), and Northern District of New York (Syracuse, Utica, Binghamton, and Albany) each had three unsealed cases, while the Central District of California (Los Angeles), the Eastern District of Michigan (Detroit), Middle District of Georgia (Macon), Southern District of Ohio (Cincinnati), Western District of Washington (Seattle, Tacoma), and Southern District of New York (Manhattan, Bronx, and Westchester County) had two apiece.
  • Eleven of the 62 unsealed cases were brought against hospitals and hospital systems. Other frequently-sued defendant types included outpatient clinics, pharmaceutical or biotech companies, and physicians or physician practice groups, which were named as defendants in seven of the 62 unsealed cases.
  • Former employees brought 44 of the 62 cases, accounting for 71% of the 62 unsealed cases. Another five relators were current employees. Two cases were brought by former business partners of the defendants.
  • None of the cases was unsealed within the 60-day period specified by statute. The shortest time under seal was 92 days, while the longest time under seal was six years and eight months. The average time under seal for this group of unsealed cases was 671 days, or just under two years. However, 15 cases — or just about a quarter of the 62 unsealed cases — were unsealed within one year of filing.

Featured Cases

United States ex rel. Emerson v. Signature Healthcare, LLC, No. 1:15-cv-00027 (M.D. Tenn.)

Complaint Filed: March 27, 2015

Complaint Unsealed: June 7, 2018

Intervention Status: The government intervened on December 4, 2017 for purposes of settlement.

Claims: False Claims Act (“FCA”), 31 U.S.C. § 3729 et seq.

Defendants’ Businesses: Defendants own and operate approximately 115 long-term health and rehabilitation centers providing skilled nursing services to patients.

Relators: Kristi Emerson and LeeAnn Tuesca

Relators’ Relationship to Defendants: The relators are currently employed by Signature Healthcare as occupational therapists.

Relators’ Counsel: David W. Garrison, Jerry E. Martin, and Seth Marcus Hyatt of Barrett Johnston Martin & Garrison, LLC, and James E. Barz and Robert K. Lu of Robbins Geller Rudman & Dowd LLP.

Summary of Case: The relators, both occupational therapists at the Signature Columbia facility in Tennessee, alleged that Signature Healthcare engaged in a company-wide scheme to defraud the U.S. government by billing Medicare for unnecessary physical, occupational, and speech-language therapy, or for services that were purportedly never provided to patients. Specifically, the relators claimed that Signature Healthcare’s regional officers and managers demanded that 90% of its Medicare Part A patients who were receiving therapy needed to be placed in the Ultra High (RU) or Very High (RV) Resource Utilization Groups (RUGs), regardless of patient need for physical or speech therapy or ability to tolerate such levels of therapy. These regional officers and managers allegedly inflated therapy times to artificially elevate patients to higher paying RUGs and also encouraged others to record therapy minutes for patients who did not receive therapy. In addition, the relators claimed that these regional officers and managers demanded that Medicare Part B patients be scheduled for unnecessary therapy when there were not enough Medicare Part A patients at the facility to keep productivity high. Signature Healthcare also allegedly routinely failed to bill physical therapy co-pays to Medicare Part B patients to avoid objections to the unnecessary therapy.

Similar allegations were advanced in a related case, United States ex rel. Burdett v. Signature Healthcare, LLC, No. 3:15-cv-00497 (M.D. Tenn.), in which the relators were Jacqueline Burdett, Signature Healthcare’s Medical Records Director, and Steve Appleton, a Licensed Physical Therapy Assistant employed at Signature Healthcare’s Westmoreland facility in Tennessee. There, the relators alleged that Signature Healthcare was engaged in a company-wide scheme to defraud the government by billing for unnecessary therapy sessions and sessions that were not actually provided to Medicare and TRICARE patients.

Current Status: The United States intervened on May 30, 2018 and entered into a Settlement Agreement with the defendants on June 8, 2018. Pursuant to this Settlement Agreement, defendants agreed to pay $30 million to the United States, plus interest at 2.375% from November 9, 2017, and contingency payments up to $5 million. The settlement amount is payable in installments, due in full by June 30, 2024. In addition to the Settlement Agreement, Signature Healthcare agreed to a Corporate Integrity Agreement with the Office of Inspector General for the Department of Health and Human Services (“OIG”), which became effective as of May 25, 2018. The complaint was dismissed and unsealed in part on June 14, 2018.

Reasons to Watch: This case is in line with a 2015 OIG report, entitled “The Medicare Payment System for Skilled Nursing Facilities Needs to be Reevaluated” and the OIG’s 2016 Work Plan, which announced that the OIG planned to review skilled nursing facility (“SNF”) compliance with the SNF prospective payment system rules. The OIG is aware that SNFs are more frequently billing Medicare at the highest RUGs for therapy, even though reported beneficiary characteristics remain constant and do not indicate a higher need for therapy. As this case demonstrates, SNF therapy times will continue to be subject to scrutiny to ensure that providers are not artificially recording higher RUGs to achieve higher reimbursement.

United States ex rel. Davis v. Southern SNF Management, Inc., No. 1:13-cv-00384-WS-M (S.D. Ala.)

Complaint Filed: July 29, 2013

Complaint Unsealed: July 17, 2018

Intervention Status: The government intervened on July 13, 2018 for purposes of settlement.

Claims: FCA, 31 U.S.C. § 3729 et seq.

Defendants’ Businesses: Defendants are management companies that own and operate multiple skilled nursing facilities in Florida and Alabama.

Relators: LaWanda M. Davis, Tramercier J. Donald, and Megan Dinkins

Relators’ Relationships to Defendants: The relators are licensed therapists formerly and currently employed at SNF facilities owned and operated by Defendants.

Relators’ Counsel: Samuel A. Cherry, Jr. of The Cochran Firm; Casey M. Preston, Gary L. Azorsky, and Jeanne A. Markey of Cohen Millstein Sellers & Toll, PLLC; and Sarah Hubbard of The Hubbard Law Firm

Summary of Case: The relators alleged that the defendant management companies implemented a scheme across the SNFs they managed to defraud the U.S. government by billing Medicare and TRICARE for unnecessary physical, occupational, and speech-language therapy or for services that were never provided to patients. Specifically, the relators claimed that Southern SNF Management demanded that all or almost all Medicare and TRICARE patients receive the amount of therapy time needed to be placed in the Ultra High (RU) Resource Utilization Group (RUG), regardless of whether patients needed physical or speech therapy or could tolerate such levels of therapy. Allegedly, SNF managers also falsely inflated therapy times to artificially elevate those patients to higher billing RUGs. In addition, the relators claimed that Southern SNF Management demanded that terminally ill and otherwise frail Medicare beneficiaries with severe cognitive impairments be assigned to unnecessarily high levels of therapy and as a result of the strain caused by such therapy were injured or died.

Current Status: The United States intervened on July 13, 2018 and entered into a Settlement Agreement with the defendants on July 18, 2018, pursuant to which defendants agreed to pay $10 million to the United States. The complaint was dismissed and unsealed in part on June 14, 2018.

Reasons to Watch: Similar to the Signature Healthcare cases summarized above, this case highlights the risks healthcare management service organizations may face when encouraging the SNFs they manage to record higher therapy times to affect RUG assignment and thereby increase reimbursement.

United States ex rel. Erickson v. Insys Therapeutics Inc., No. 2:16-cv-02956-JLS-AJW (C.D. Cal.)

Complaint Filed: April 29, 2016

Complaint Unsealed: May 11, 2018

Intervention Status: The government intervened on April 13, 2018.

Claims: FCA, 31 U.S.C. § 3729 et seq., Anti-Kickback Statute (“AKS”), 42 U.S.C. § 1320a-7b

Defendant’s Business: Defendant Insys Therapeutics, Inc. (“Insys”), a pharmaceutical company, is the maker of Subsys, an oral fentanyl spray used for the treatment of cancer pain in adults.

Relators: Allison Erickson and Sara Lueken

Relators’ Relationship to Defendant: Relators are employees of Prime Therapeutics, a pharmacy benefits manager (“PBM”) that processed Medicare Part D claims for Insys.

Relators’ Counsel: Bart D. Cohen of the Law Office of Bart D. Cohen; Jeffrey S. Gleason, Jamie R. Kurtz and Jill S. Casselman of Robins Kaplan LLP.

Summary of Case: Insys manufactures a fentanyl drug known as Subsys. The FDA approved Subsys to treat cancer patients suffering from severe pain but did not approve the drug for any other use. Medicare only pays for Subsys if the patient has cancer and is opioid intolerant (i.e., cannot be treated effectively for pain using conventional opioid drugs). The relators, employees of a PBM that administered Medicare Part D prescription drug plans, alleged that Insys falsified patient information to obtain the PBM’s approval to prescribe Subsys to Medicare patients. The relators alleged multiple instances of calls to the PBM by people identifying themselves as employees of prescribers seeking approval to prescribe Subsys to their patients whom relators later realized were actually Insys employees. These employees were supposedly part of a no-cost service agreement between Insys and prescribers in which the Insys unit would seek Medicare authorization on behalf of the medical professionals. According to the relators, Insys employees provided false information about patients to ensure that a prescriber’s request was approved, even though many of the patients did not actually qualify for Subsys because they were not suffering from cancer.

The United States intervened on April 13, 2018, and filed a complaint in intervention alleging two additional acts of misconduct against Insys. First, the United States claimed Insys operated a “speaker program” that was ultimately a way to disguise unlawful kickbacks to prescribers. Insys allegedly paid large sums of money to prescribing doctors to produce presentations about Subsys, but the physicians ultimately did not provide any substantive presentations. Allegedly, many of the speaker program participants only presented to their own office staffs, with many of such staff members attending multiple presentations. Moreover, according to information from the Medicare claims database, the participants in the speaker program were among the largest prescribers of the medication, with some of them prescribing millions of dollars of government-reimbursed Subsys. Second, the United States alleged that Insys targeted its marketing strategy to patients not suffering from cancer. Thus, the government’s complaint contended that most of the presentation speakers specialized in fields other than oncology and management urged Insys representatives to push for off-label sales.

Current Status: In August 2018, Insys announced that a settlement in principal had been reached by the parties. However, no final settlement agreement has been officially filed in the court at this time. The court unsealed the case in part on May 11, 2018.

In December 2016, the federal court in Boston unsealed an indictment of several top Insys executives for alleged criminal violations arising from the scheme alleged in the qui tam actions described above. A superseding indictment was unsealed in October 2017 naming Insys founder John Kapoor. All defendants have pleaded not guilty, and the criminal case is likely to go to trial sometime in 2019.

Reasons to Watch: This case sits at the intersection between fraud and abuse enforcement and the country’s persistent opioid crisis. The approved indications for prescribing Subsys entail only a small risk of abuse because use is limited to palliative care for terminal cancer patients. Off-label prescribing of powerful opioids such as Subsys results not only in false claims but also has the potential to exacerbate opioid dependence and abuse in patients suffering from chronic pain. As such, cases at this intersection will continue to be a strong focus for government action.

The kickback claims in this case also provide an example of the growing enforcement focus on inducements offered to physicians and prescribers by pharmaceutical manufacturers. Recent cases such as this have shown that the government will look closely at speaker programs to ensure that compensation is reasonable and that the services provided are legitimate.

Finally, this case is a significant illustration of the government’s increasing reliance on prescribing information from the Medicare claims database to establish the volume and scope of the allegedly improper prescribing practices – in this matter of Subsys. Relators have begun taking advantage of the ability of private citizens to access such databases to help document allegedly false or fraudulent claims. The government’s complaint in intervention here signals the government’s increasing use of Medicare data in cases, such as this one, in which it decides to intervene.

United States ex rel. Van Der Boom v. Precision Medical Products, Inc., No. 2:15-cv-00428-MCE-KJN (E.D. Cal.)

Complaint Filed: February 24, 2015

Complaint Unsealed: May 23, 2018

Intervention Status: The government intervened on May 18, 2018 for purposes of settlement.

Claims: FCA, 31 U.S.C. § 3729 et seq., AKS, 42 U.S.C. § 1320a-7b, and California False Claims Act (“CFCA”), Cal. Gov. Code § 12650 et seq.

Defendants’ Business: Defendant Precision Medical Products Inc. (“PMP”) is a supplier of durable medical equipment to patients covered by Medicare, MediCal (the California Medicaid program), and Tricare (the federal military health insurance program). Defendant Jeremy Perkins is the founder and owner of PMP. Defendant Marc Reynolds serves as the chief financial officer of PMP.

Relators: Gant Van Der Boom (“Van Der Boom”), Darleen Roland (“Roland”), and Jena Burns (“Burns”).

Relators’ Relationships to Defendants: Van Der Boom is a former PMP sales representative. Roland is the owner of Efficiency Plus Medical Billing (“EPMB”), and Burns is the billing manager of EPMB, which at one time had an agreement to provide medical billing services to PMP.

Relators’ Counsel: Leslie Sindelar Guillon, Gary B. Callahan, and Tatiana Filippova of Arnold Law Firm, and Tiffany B. Wong of Cotchett, Pitre & McCarthy, LLP.

Summary of Case: Shortly after PMP was formed, the company hired relator Van Der Boom as a sales representative. Throughout his time as a PMP employee, Van Der Boom allegedly received commission-payments based on his sales of Medicare, MediCal, and Tricare reimbursed PMP DME. The relators claim that these commissions were unlawful kickbacks because the intention was to reward sales representatives for obtaining orders of DME that were ultimately paid for by the government. The relators also allege that PMP provided fraudulent prescriptions for Medicare-reimbursed DME. While processing PMP’s medical bills, relators Roland and Burn assert that they noticed physician signatures that did not seem to be authentic. At the same time, relator Van Der Boom allegedly witnessed the forgery of physician signatures on order forms, either by tracing an authentic signature through a light source or using a form with a pre-printed physician signature. In addition, PMP purportedly waived Medicare patient co-pays to help patients avoid financial hurdles in obtaining PMP products and either sent patients cheaper equipment than was prescribed or never sent the ordered equipment at all, but nonetheless, it still submitted the original prescription to Medicare for reimbursement. By way of example, Relators Roland and Burns alleged that PMP would remove the hinge from the prescribed knee device and attach it to a cheaper knee device before providing the less expensive product to the patient. Relator Van Der Boom further asserts that when he questioned PMP about these alleged practices, he was demoted and ultimately terminated.

Current Status: On May 4, 2018, the parties entered into a $1.9 million settlement agreement, and the United States then intervened on May 18, 2018 for purposes of settlement. The case was then dismissed by the court on June 8, 2018.

Reasons to Watch: This case demonstrates how potentially fraudulent conduct may be visible to employees dispersed throughout a company. The relators were employed in different areas within PMP but nonetheless witnessed the same alleged misconduct. For example, the claims of fraudulent signatures were noticed by billing administrators but also were observed within the sales department. This indicates that the compliance function within any health care business should be active throughout the entire organization. Conduct implicating the fraud and abuse laws can occur in many parts of a health care entity, and a robust compliance program requires training and reporting avenues for all.

Health Care Qui Tam Litigation Trends

Mintz maintains a database of unsealed health care qui tam actions. This enables us to follow and analyze trends in the cases that have been unsealed. The following are some trends in qui tam filings against health care-related entities in the 12 months that ended August 31, 2018:

Where were cases filed? Although cases were unsealed in jurisdictions throughout the country, some interesting trends have emerged as to jurisdictions where the most cases have been unsealed:

Qui Tam 11-2018 Court Jurisdiction

For the 12-month period that ended on August 31, the Middle District of Florida (Tampa, Orlando, and Jacksonville) continued to be the leading jurisdiction for unsealed cases, followed by the Central District of California (including Los Angeles and Santa Barbara), the Southern District of Florida (Miami, Fort Lauderdale, and West Palm Beach), the District of Columbia, and the Eastern District of New York (Brooklyn, Queens, and Long Island).

Who brought the cases? The ranks of relators are beginning to diversify. In the 12 months that ended August 31, 2018, current and former employees – mostly the latter – continued to dominate the ranks of relators, accounting for 59% of all cases. But significant numbers of relators are now found among customers, industry experts, business partners, consultants, and patients.

Qui Tam 11-2018 Relators Relation

How frequently did the government intervene?

Qui Tam 11-2018 Government Intervention

Intervention rates continue to be extremely low, with the government electing to intervene in only 16% of cases unsealed in the 12 months that ended August 31, 2018.

[View source.]

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Mintz | Attorney Advertising

Written by:

Mintz
Contact
more
less

Mintz on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.